Eris Lifesciences Ltd (ERIS):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Eris Lifesciences Ltd (ERIS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8227
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:29
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:インド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Eris Lifesciences Ltd (Eris Lifesciences) is a health care products and service provider. The company offers glimepride, telmisertan, methylcobalamin and combinations, vitamin d, rabeprazole, olmesartan, mecobalamin colecalciferol, teneligliptin, rosa canina extract, cilnidipine, atorvastatin, conventional iron, gliclazide, rosuvastatin and sultamicillin products. It provides medicines to cardiovascular, anti-diabetes, vitamins and nutrients, gastroenterology, gynaecology, pediatrics, respiratory, neurology, psychiatry, and pain and analgesics. Eris Lifesciences provides anti diabities medicines such as glimepiride and combinations, teneligliptin and combinations, gliclazide and combinations and voglibose and combinations. The company offers products in the form of tablets, capsules and sachets. It markets through chemist outlets. The company has manufacturing facility located at Assam. Eris Lifesciences is headquartered in Ahmedabad, Gujarat, India.

Eris Lifesciences Ltd (ERIS) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Eris Lifesciences Ltd, Medical Devices Deals, 2012 to YTD 2018 10
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Eris Lifesciences Acquires Branded Generics Business from Strides Shasun for USD76.7 Million 12
Eris Lifesciences Acquires 40 Trademarks from Amay Pharma for USD5 Million 14
Licensing Agreements 15
Aprica Healthcare Enters into Licensing Agreement with Eris Lifesciences 15
Equity Offering 16
Eris Lifesciences Raises USD270 Million in IPO 16
Acquisition 18
Eris Lifesciences Acquires UTH Healthcare for USD2 Million 18
Eris Lifesciences Acquires Additional 14% Stake in Kinedex Healthcare for USD2 Million 19
Eris Lifesciences Acquires 61.48% Stake in Kinedex Healthcare for USD9.2 Million 20
Eris Lifesciences Acquires Aprica Healthcare 21
ChrysCapital May Sell its Stake in Eris Lifesciences 22
Nrim May Acquire Additional Stake in Kinedex Healthcare 23
Nrim Invests in Kinedex Healthcare 24
Eris Lifesciences Ltd – Key Competitors 25
Eris Lifesciences Ltd – Key Employees 26
Eris Lifesciences Ltd – Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 28
Other Significant Developments 28
Aug 17, 2017: Eris Lifesciences Announces the Dhifting of the Registered Office of the Company 28
Appendix 29
Methodology 29
About GlobalData 29
Contact Us 29
Disclaimer 29

List of Tables
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Eris Lifesciences Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Eris Lifesciences Ltd, Medical Devices Deals, 2012 to YTD 2018 10
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Eris Lifesciences Acquires Branded Generics Business from Strides Shasun for USD76.7 Million 12
Eris Lifesciences Acquires 40 Trademarks from Amay Pharma for USD5 Million 14
Aprica Healthcare Enters into Licensing Agreement with Eris Lifesciences 15
Eris Lifesciences Raises USD270 Million in IPO 16
Eris Lifesciences Acquires UTH Healthcare for USD2 Million 18
Eris Lifesciences Acquires Additional 14% Stake in Kinedex Healthcare for USD2 Million 19
Eris Lifesciences Acquires 61.48% Stake in Kinedex Healthcare for USD9.2 Million 20
Eris Lifesciences Acquires Aprica Healthcare 21
ChrysCapital May Sell its Stake in Eris Lifesciences 22
Nrim May Acquire Additional Stake in Kinedex Healthcare 23
Nrim Invests in Kinedex Healthcare 24
Eris Lifesciences Ltd, Key Competitors 25
Eris Lifesciences Ltd, Key Employees 26
Eris Lifesciences Ltd, Subsidiaries 27

List of Figures
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Eris Lifesciences Ltd, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Eris Lifesciences Ltd (ERIS):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Industrial and Commercial Bank of China Ltd:企業のM&A・事業提携・投資動向
    Industrial and Commercial Bank of China Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Industrial and Commercial Bank of China Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, det …
  • Ontario Power Generation Inc:企業の戦略的SWOT分析
    Ontario Power Generation Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • El Al Israel Airlines Ltd.:企業の戦略・SWOT・財務情報
    El Al Israel Airlines Ltd. - Strategy, SWOT and Corporate Finance Report Summary El Al Israel Airlines Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Australia and New Zealand Banking Group Ltd:戦略・SWOT・企業財務分析
    Australia and New Zealand Banking Group Ltd - Strategy, SWOT and Corporate Finance Report Summary Australia and New Zealand Banking Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation …
  • CorEnergy Infrastructure Trust Inc (CORR):企業の財務・戦略的SWOT分析
    CorEnergy Infrastructure Trust Inc (CORR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • Lamellar Biomedical Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Lamellar Biomedical Ltd (Lamellar Biomedical) is a biotechnology company that develops medical products using based on mimetics of extra-alveolar lamellar bodies. The company develops products using its proprietary Lamellasome technology that are mimetics of native extra-alveolar lamellar th …
  • Unitil Corp (UTL):企業の財務・戦略的SWOT分析
    Summary Unitil Corp (Unitil) is an interstate electricity and natural gas utility company. The company offers construction, operation and maintenance of gas and electric distribution systems. Unitil offers business operations such as electricity distribution, gas distribution utility operations and …
  • RHI Magnesita N.V.:企業の戦略・SWOT・財務情報
    RHI Magnesita N.V. - Strategy, SWOT and Corporate Finance Report Summary RHI Magnesita N.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Coats Group plc:企業のM&A・事業提携・投資動向
    Coats Group plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Coats Group plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • Terme Dobrna D.D.
    Terme Dobrna D.D. - Strategy, SWOT and Corporate Finance Report Summary Terme Dobrna D.D. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Ultra Electronics Holdings plc:企業のM&A・事業提携・投資動向
    Ultra Electronics Holdings plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Ultra Electronics Holdings plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers a …
  • Petoro AS:企業の戦略的SWOT分析
    Petoro AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • Samsung C&T Corp:企業のM&A・事業提携・投資動向
    Samsung C&T Corp - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Samsung C&T Corp Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), dives …
  • Impresa Pizzarotti & C. S.p.A.:企業の戦略・SWOT・財務情報
    Impresa Pizzarotti & C. S.p.A. - Strategy, SWOT and Corporate Finance Report Summary Impresa Pizzarotti & C. S.p.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Canara Bank (CANBK):企業の財務・戦略的SWOT分析
    Canara Bank (CANBK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • InMed Pharmaceuticals Inc (IN):医療機器:M&Aディール及び事業提携情報
    Summary InMed Pharmaceuticals Inc (InMed), formerly Cannabis Technologies Inc, is a pre-clinical stage biopharmaceutical company which develops, produces and markets plant cannabinoid based medicines. The company's pipeline products include INM-750, INM-405, and INM-085. Its products finds applicati …
  • Endo International Plc (ENDP):企業の財務・戦略的SWOT分析
    Endo International Plc (ENDP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Novelis Inc
    Novelis Inc - Strategy, SWOT and Corporate Finance Report Summary Novelis Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Innate Pharma SA (IPH):企業の財務・戦略的SWOT分析
    Summary Innate Pharma SA (Innate Pharma) is a biotechnology company developing antibodies to treat cancer by harnessing the immune system. It offers Lumoxiti, a CD22-directed immunotoxin for the treatment of relapsed or refractory hairy cell leukemia (HCL). The company is investigating drugs against …
  • Condor Petroleum Inc (CPI):石油・ガス:M&Aディール及び事業提携情報
    Summary Condor Petroleum Inc. (Condor) is an independent upstream oil and gas company. The company through its subsidiaries, acquires, explores, produces and markets oil and gas. It has operational presence in Kazakhstan and Turkey. The company operates on the Pre-Caspian basin, a prolific region th …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆